ARTICLE

FindCenter AddIcon

We Can No Longer Ignore the Potential of Psychedelic Drugs to Treat Depression

By Robin Carhart-Harris — 2020

At Imperial College we’ve been comparing psilocybin to conventional antidepressants—and the results are likely to be game-changing.

Read on www.theguardian.com

FindCenter Post-Image

Experimental Treatments Changed the Course of the AIDS Epidemic; We Need the Same Approach to Mental Illness Today | Commentary

Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.

Article
Monnica Williams, Morgan Campbell
2021
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

Article
Patricia Kubala
2020
FindCenter AddIcon
FindCenter Post-Image

Mental Disorder Within the Neurodiversity Paradigm

Can neurodiversity proponents keep the notion of mental pathology?

Article
Robert Chapman
2019
FindCenter AddIcon
FindCenter Post-Image

A Psychedelic Drug Passes Big Test for PTSD Treatment

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy.

Article
Rachel Nuwer
2021
FindCenter AddIcon
FindCenter Post-Image

Repeated Ketamine Infusions Reduce PTSD Symptom Severity

Repeated intravenous (IV) ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a new study.

Article
ScienceDaily
2021
FindCenter AddIcon

EXPLORE TOPIC

Psilocybin